Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. - Wikidata - awgldk - TriplyDB

Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.

Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.

http://www.wikidata.org/entity/Q39568148

about

The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases Bile acid signaling in metabolic disease and drug therapy Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease.Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players.Potential epigenetic mechanism in non-alcoholic Fatty liver disease Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver.MicroRNAs and Noncoding RNAs in Hepatic Lipid and Lipoprotein Metabolism: Potential Therapeutic Targets of Metabolic Disorders.Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1.Systematic analysis of the regulatory functions of microRNAs in chicken hepatic lipid metabolism.The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis.MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.The microRNA regulatory network: a far-reaching approach to the regulate the Wnt signaling pathway in number of diseases.Role of MicroRNAs in NAFLD/NASH.miRNA and cholesterol homeostasis.The multifactorial nature of microRNAs in vascular remodelling.Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?HDL and microRNA therapeutics in cardiovascular disease.MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.miRNAs in non-alcoholic fatty liver disease.The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.MicroRNA-206 Prevents the Pathogenesis of Hepatocellular Carcinoma Via Modulating Expression of cMet and Cdk6.MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis Identification of microRNAs controlling hepatic mRNA levels for metabolic genes during the metabolic transition from embryonic to posthatch development in the chicken.MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1.Systems genetics identifies a co-regulated module of liver microRNAs associated with plasma LDL cholesterol in murine diet-induced dyslipidemia.Mir-24 regulates hepatocyte apoptosis via BIM during acute liver failure.Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing miR-195/miR4668 maturation.Integrative analysis of microRNAs and mRNAs revealed regulation of composition and metabolism in Nelore cattle.MicroRNA and Adipogenesis.MicroRNAs as Potential Regulators of Glutathione Peroxidases Expression and Their Role in Obesity and Related Pathologies.Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease Differences in circulating microRNA signature in Prader-Willi syndrome and non-syndromic obesity

P2860

Q26750496-A79EEF9C-24CE-4DA6-B97A-AB6394C058C5 Q28244875-08D81143-0798-4779-933D-944F7BB51589 Q30400120-799E8455-EFFA-4CB3-896E-64D1C7AA7A87 Q33567332-4AF610D6-8987-491A-92ED-C80E9473BCC7 Q33807881-4F4AB8A9-E5B1-4D7D-9E52-1385C51F50DD Q34821020-4821A705-4A27-4220-A50F-7294B6C685B1 Q35380845-7E821B00-CB09-434B-BDBD-45F7B54E3CD8 Q35922081-999511BD-079A-430C-811A-A9069BB9EFE6 Q36599274-A5AF2800-3137-4F40-9AAC-FCA4A2040E60 Q36764809-9391DE1F-2A9D-46B1-8FC0-B5CF0E30E2FB Q36898227-755EBEF5-F988-4E56-B0C6-ACD957794B6E Q37184805-0B73B850-DAD8-4AF7-928F-7922C1C980F3 Q37408646-2AE6EE01-8AA4-41BC-BA27-6E451B582858 Q38297030-3273ADA6-1FF9-4A93-967E-D610968F11D3 Q38622178-2C1911D3-7D82-4292-A1DA-52B780BC018D Q38697221-183F636E-8028-40C1-BF8E-110D6A9D3D8A Q38700512-441D9D29-8D74-4415-BA10-32BD02EE8197 Q38749173-2FD5AD01-D24C-4B94-B9A8-3B10F968B7D7 Q38813514-33531DAA-DCA5-4B12-9103-E68C7324A84F Q38824208-9032F584-2563-49F9-B7BE-B633F01E9A7D Q38954546-4C9BF9AA-EAE3-4A02-9FBA-63C1A2511877 Q38966905-868D350A-2966-4511-8685-2532A4E3C010 Q39072215-8B4A76E2-1649-4355-A674-CAE88D4D3B2F Q40061048-BB84DCB9-674F-40B7-9BAD-ECD627A59D20 Q40132515-D83A7BA0-F57B-4BDC-8D8B-34C6BDB53E51 Q41495543-1A3A9C40-F8B0-4A64-BB87-0019A9388627 Q41611022-3313BADB-A2A4-40BE-9710-55384B922550 Q44303902-1EFAE9A7-5190-4BBB-9DD3-78168C3D97EF Q46067590-09F664C9-9B66-4E03-A273-7EB423D0CAB3 Q47125978-7F48F2F4-ACDF-49DB-86C1-7A60AEAE77DA Q49471259-AD3F2EC3-6B0F-4D29-83B7-B59FFBB07C32 Q49589296-0FF909FD-FEC1-4457-BDE8-448982747516 Q50957766-A776322F-E9F4-423F-8C2C-FA33D8E0EB15 Q55128512-0CE0C7A1-9073-4871-8986-AC0FE0CAFB6C Q57067876-30195AB2-DAE2-4593-9D76-C2850101A007 Q57818910-2A9DAC4C-A45D-4418-A644-535267BB77F1

P2860

Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.

http://www.wikidata.org/entity/Q39568148

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.

@en

Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.

@nl

type

label

Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.

@en

Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.

@nl

prefLabel

Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.

@en

Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.

@nl

P1433

Q39568148-776C4001-0DF8-4094-BD75-7F73964B16E8

P1476

Q39568148-2F50EBAA-38FD-49E2-AA60-F1C2F4A21271

P2093

Q39568148-435FC8BD-DB46-40F9-8017-619EC77A087B

Q39568148-582DC3EB-8FE5-4807-A128-F154D49C24C7

Q39568148-6FE3CE6D-2BB0-4FF6-A502-065C9D9ACD04

Q39568148-81C5DA14-EE76-42FB-9BBD-4CA844D1497E

Q39568148-B881B23A-5F50-4DE7-83EA-F48944C4DA6D

Q39568148-C20D5E27-7915-4CE5-8265-4525FD8D6276

Q39568148-CC039625-84B3-49F8-B269-D30B4A743F05

P2860

Q39568148-0EB1D872-85E1-42E2-A667-B8D9924F3D88

Q39568148-0F1B2429-1989-4156-98F2-10B9D2915C72

Q39568148-0F670EB4-E14E-4B15-BA61-E8642F97515A

Q39568148-16F8D5D8-FD85-466E-A7AA-62E0519479B6

Q39568148-19E864C2-65BB-4E02-BD41-2F6DD3B02451

Q39568148-1B593EB6-F2FF-4383-8F6B-F38A3A860EE6

Q39568148-2998AAA1-1FC1-4A30-B741-32EC4F97495E

Q39568148-29E92F5F-BCAD-4676-8F4B-45488E18E80F

Q39568148-30C44DF7-5E6F-4974-8C12-5449D027E875

Q39568148-3F072356-A095-4C9C-9674-830E426899D4

P304

Q39568148-ECF3C922-4A72-4337-A9D1-51173E33BF0B

P31

Q39568148-951DA4D0-E2F0-4BE9-9BA2-1DCDEE773CF4

P356

Q39568148-66846F07-671D-41FA-9407-0EE821A7EC3F

P407

Q39568148-46DB11F8-8F0C-49B9-90BD-7422A16E512A

P433

Q39568148-2F26BF39-92EE-49EA-93DF-A241A90BF046

P478

Q39568148-A94E88B9-FE84-40F1-9701-87D8F89A8A2D

P577

Q39568148-C2C08D33-A8CF-48FA-A088-D0DDA7912D4E

P698

Q39568148-168EF763-7167-4838-AF60-E52BDC774EB9

P921

Q39568148-3097CE90-1446-4CBB-B1A3-23E4CEFCC877

Q39568148-94FC8797-0233-4DD3-ABF6-C2DD506A709F

P932

Q39568148-0204708F-5F8B-46ED-8F57-939A3485B781

P356

P1433

P1476

Inhibition of microRNA-24 expr ...... cumulation and hyperlipidemia.

@en

P2093

Clifford J Steer

http://www.w3.org/2001/XMLSchema#string

Guisheng Song

http://www.w3.org/2001/XMLSchema#string

Heng Wu

http://www.w3.org/2001/XMLSchema#string

Holger Willenbring

http://www.w3.org/2001/XMLSchema#string

Hong Xiao

http://www.w3.org/2001/XMLSchema#string

Raymond Ng

http://www.w3.org/2001/XMLSchema#string

Xin Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER

Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins

The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb.

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood

starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data

Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

Most mammalian mRNAs are conserved targets of microRNAs

Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes

MicroRNAs as pharmacological targets in diabetes

P304

554-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27153

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24677249

http://www.w3.org/2001/XMLSchema#string

P921

P932

4809671

http://www.w3.org/2001/XMLSchema#string